Health5 outlets · 1 countries

ESMO 2026: Marengo’s bispecific antibody shrinks 8 tumor types in Phase 2

This briefing item

First published 35 hours ago (Oct 23, 2026, 7:00 PM UTC) · latest update Oct 23, 2026, 7:00 PM UTC

Independent

Public broadcasters

State-backed

Stance mix in this cluster

Left 0Neutral 5Right 0

Global · 5

Cross-referenced facts

What more than one outlet reports

Prism keeps a sentence only when at least two write-ups share the same core details. Adjectives that signal a take are stripped. This is not a verdict — it is the overlapping record.

Headlines in this cluster diverge enough that no sentence repeated cleanly. Shared names and figures are listed below; treat single-source claims as unverified here.

001ESMO2026

Where coverage diverges3

Claims that appeared in only one write-up, each labeled by outlet.

Nature · Independent · Global
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.
AOL.com · Independent · Global
Marengo Therapeutics Presents Phase 2 STARt-001 Results at ESMO 2026 Demonstrating Tissue-Agnostic Single-Agent Activity of Invikafusp Alfa in TMB-H Solid Tumors Mostly Unresponsive to Immune Checkpoint Blockade.
Mass General Brigham · Independent · Global
Novel cancer immunotherapy drug generates promising clinical trial results.

Each outlet, labeled5

Sources are ordered left → neutral → right so the spread is visible. Stance is a coarse editorial label for comparison, not a moral score. Timestamps are the time each item entered the feed.